Skip to main content
. 2024 Oct 11;11(6):e200321. doi: 10.1212/NXI.0000000000200321

Table 3.

PK/PD Levels at Time of Detection of N/NE T2 Lesions in Q6W and Q4W Groups

Participant no. Visit when N/NE T2 lesions identified Natalizumab Ctrough at time of N/NE T2 lesions (μg/mL) α4-Integrin saturation on MNC at time of N/NE T2 lesions (%)
Q6W 09 Week 24 10.8 (week 12)a 69.3 (week 12)a
14 Week 48 0 30.4
15 Week 72 17.6 80.0
18 Week 24 7.68 69.1
19 Week 72 0 64.6 (week 60)a
20 Week 48 7.5 72.8
25 Week 48 0 23.5 (week 36)a
26 Week 48 12.8 69.4
28 Week 24 24.8 84.8
Q4W 02 Week 24 1.89 53.1
07 Week 24 61.4 84.9
08 Week 72 38.5 89.9
10 Week 72 52.1 85.8
22 Week 48 14.4 76.3
23 Week 48 25.8 79.5
24 Week 48 9.52 77.2
27 Week 24 54.5 65.4

Abbreviations: Ctrough = trough concentrations; MNC = mononuclear cell; N/NE = new/newly enlarging; PD = pharmacodynamic; PK = pharmacokinetic; Q4W = every 4 weeks; Q6W = every 6 weeks.

a

Ctrough and/or α-integrin saturation were not available at the time of lesion identification; data from the visit closest to lesion detection (week in parentheses) are shown.